Khan Arif, Redding Nick, Brown Walter A
Northwest Clinical Research Center, Bellevue, WA 98004, USA.
J Psychiatr Res. 2008 Aug;42(10):791-6. doi: 10.1016/j.jpsychires.2007.10.004. Epub 2007 Nov 26.
Our objective was to assess the persistence of the placebo response during at least 12 weeks of continued placebo administration in depressed patients who have responded to 6-8 weeks of acute placebo treatment. We identified 8 placebo-controlled antidepressant trials with a total of 3,063 depressed patients in which, after acute phase placebo treatment, placebo was continued for more than 12 weeks. The number of patients entering the continuation phase and percentages relapsing during this phase were determined. Based on the total number of patients entering the continuation phase 79% of placebo responders remained well (did not meet relapse criteria) during this phase compared to 93% of antidepressant responders. Although significantly more patients on placebo than on antidepressants relapsed in the continuation phase, 4 out of 5 placebo responders stayed well. The widely held belief that the placebo response in depression is short-lived appears to be based largely on intuition and perhaps wishful thinking.
我们的目标是评估在接受了6 - 8周急性安慰剂治疗后有反应的抑郁症患者中，持续给予安慰剂至少12周期间安慰剂反应的持续性。我们确定了8项安慰剂对照的抗抑郁试验，共有3063名抑郁症患者，在急性期安慰剂治疗后，安慰剂持续使用超过12周。确定了进入延续期的患者数量以及在此期间复发的百分比。基于进入延续期的患者总数，在此期间79%的安慰剂反应者病情保持良好（未达到复发标准），而抗抑郁药反应者为93%。虽然在延续期使用安慰剂复发的患者明显多于使用抗抑郁药的患者，但5名安慰剂反应者中有4名病情保持良好。普遍认为抑郁症中的安慰剂反应是短暂的，这一观点似乎很大程度上基于直觉，也许还有一厢情愿的想法。
